Will atezolizumab be a new standard for adjuvant treatment of NSCLC patients?
Statistically significant improvement in disease-free survival demonstrated in IMpower010. It is suggested that atezolizumab may become new standard for adjuvant treatment of stadium IB – IIIA NSCLC patients with PD-L1 ≥1%. The question is whether disease-free survival is enough to change clinical practice.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.